Atlanta 2/20/2013 5:47:38 AM
La Jolla Pharmaceutical Co. (Stock Symbol: OTN: LJPC) is now on LinkMyStock.com
La Jolla Pharmaceutical Co. has joined LinkMyStock.com. Now Stock Brokers, Brokerage Firms and Investors/Shareholders from around the world who follow La Jolla Pharmaceutical Co. can link directly to La Jolla Pharmaceutical Co. Link My Stock Hub. Brokers and Brokerage Firms that link to La Jolla Pharmaceutical Co. typically are familiar with the company and can facilitate transactions in La Jolla Pharmaceutical Co. security. Investors linking to La Jolla Pharmaceutical Co. usually are either existing shareholders looking to stay informed when La Jolla Pharmaceutical Co. posts new information or people that are simply interested in La Jolla Pharmaceutical Co. that are not yet or may never become shareholders.
LinkMyStock is a premier financial networking platform designed specifically for public companies, brokerage firms, brokers and investors. LinkMyStock.com provides a network that consists of brokers, brokerage firms and investors that can link directly to the companies that they follow. With brokers from around the world having the ability to select companies to link to that are members of Link My Stock this provides investors with the ability to locate brokers and contact them to find out more information about a company they are interested in learning more about.
LinkMyStock.com provides every member with their own hub where they post content. Content sections include; press releases, blogs, pictures, videos, Right Now status updates, events, jobs and more in order to attract more visitors and increase the number of search results along with improving indexing.
To link to the La Jolla Pharmaceutical Co. 's Link My Stock Hub sign into your Link My Stock Hub or Join Link My Stock today.
About La Jolla Pharmaceutical Co.
La Jolla Pharmaceutical Company is a biopharmaceutical company dedicated to the development of medical treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer.